Table 2.
Demographic and Clinical Characteristics of Men Receiving Statin Therapy (N=434)
| N included | HIV+ (N=230) N (%) or median (IQR) | HIV−(N=204) N (%) or median (IQR) | p value | |
|---|---|---|---|---|
| Age (years) | 434 | 51 (46, 55) | 55 (48, 62) | <0.0001 |
| Body mass index (kg/m2) | ||||
| <25 | 434 | 96 (41.7) | 54 (26.5) | |
| 25–30 | 86 (37.4) | 77 (37.7) | 0.0003 | |
| >30 | 48 (20.9) | 73 (35.8) | ||
| Race | ||||
| White | 434 | 176 (76.5) | 176 (86.3) | |
| Black | 31 (13.5) | 22 (10.8) | 0.007 | |
| Hispanic/other | 23 (10.0) | 6 (2.9) | ||
| Smoking at index visit | ||||
| Never | 434 | 60 (26.1) | 58 (28.4) | |
| Former | 118 (51.3) | 109 (53.4) | 0.51 | |
| Current | 52 (22.6) | 37 (18.1) | ||
| HDL cholesterol current (mg/dl) | 419 | 48 (40, 55) | 50 (43, 59) | 0.06 |
| LDL cholesterol current (mg/dl) | 434 | 94 (75, 115) | 92 (75, 111) | 0.39 |
| LDL cholesterol prior to statin initiation (mg/dl) | 434 | 132 (103, 156) | 140 (118, 162) | 0.004 |
| CD4+ T cell count (cells/μl) | 230 | 621 (465, 824) | — | — |
| Median (IQR) HIV RNA (men with detectable virus) | 31 | 182 (94, 17,981) | — | — |
| Chronic HCV | 427 | 7 (3.1) | 2 (1.0) | 0.13 |
| AST and/or ALT >80 U/liter | 434 | 8 (3.5) | 1 (0.5) | 0.03 |
| No medical insurance | 434 | 8 (3.5) | 5 (2.5) | 0.53 |
| No insurance coverage for medications | 434 | 17 (7.4) | 12 (5.9) | 0.53 |
| Diabetes | 336 | 27 (15.6) | 22 (13.5) | 0.58 |
| Hypertension | 426 | 111 (49.6) | 104 (51.5) | 0.69 |
| Family history of premature CHD | 434 | 50 (24.5) | 53 (23) | 0.72 |
| Framingham risk score, visit prior to starting statin therapy | ||||
| Low (<10%) | 374 | 96 (49.5) | 82 (45.6) | |
| Medium (10–20%) | 86 (44.3) | 87 (48.3) | 0.73 | |
| High (>20%) | 12 (6.2) | 11 (6.1) | ||
| On high-potency statina | 434 | 167 (72.6) | 183 (89.7) | <0.0001 |
| Current PI use | 230 | 111 (48.3) | ||
| Current EFV use | 230 | 27 (11.7) | ||
| Current PI+EFV use | 230 | 9 (3.9) | ||
| No current PI or EFV use | 230 | 101 (43.9) | ||
| PI use at visit prior to starting statin therapy | 225 | 123 (54.7) | ||
| EFV use at visit prior to starting statin therapy | 225 | 58 (25.8) | ||
| PI+EFV use at visit prior to starting statin therapy | 225 | 22 (9.8) | ||
| No PI or EFV use at visit prior to starting statin therapy | 225 | 66 (29.3) | ||
| On BAS | 434 | 2 (0.9) | 3 (1.5) | |
| On niacin | 434 | 17 (7.4) | 6 (2.9) | |
| On fibrate | 434 | 39 (17.0) | 14 (6.9) | |
| On ezetemibe | 434 | 13 (5.7) | 2 (1.0) | |
| On omega 3 | 434 | 11 (4.8) | 1 (0.5) | |
a
Atorvastatin, rosuvastatin, simvastatin.